CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.
Multiple Myeloma|Multiple Myeloma in Relapse|Multiple Myeloma Progression
DRUG: CAR-T Re-treatment
Occurrence of treatment related adverse events, assessed by CTCAE v4.0, \>= Grade 1 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment, Day 1-30 days after injection
Anti-myeloma responses, by measuring the changes of aberrant immunoglobulin in serum, Day 1-60 months|Anti-myeloma responses, multiple myeloma cells in bone marrow, Day 1-60 months
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.